Ajanta Pharma Limited has informed the Exchange regarding ''. BRSR Report for FY 2025
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajanta Pharma has submitted its Annual Report and BRSR for FY 2024-25 to the exchanges, along with the notice for its 46th AGM to be held on July 17, 2025 via video conferencing. The company reported strong consolidated results with revenue up 10% to ₹4,648 crore, EBITDA up 7% to ₹1,260 crore (27% margin), and profit after tax rising 13% to ₹920 crore. Its core Branded Generics business hit a record 74% of revenue at ₹3,394 crore (15% growth), led by India at ₹1,452 cr (+11%), Asia at ₹1,191 cr (+13%), and Africa at ₹750 cr (+28%); US Generics grew 9% to ₹1,047 crore. The company returned ₹700 crore to shareholders through dividend (₹350 cr) and buyback (₹350 cr), lifted EPS to ₹74 from ₹65, and improved ROCE to 32%. New investments include a corporate HQ in Andheri and a liquid dosage plant at Pithampur, with 34% of energy now from solar.
This is primarily a procedural filing, but it confirms a strong financial year with 13% PAT growth, industry-leading 32% ROCE, and continued shareholder rewards of ₹700 crore, including a buyback at ₹2,770 per share. The AGM on July 17 will be the key upcoming event where shareholders formally approve results and resolutions.